(4)
🔥 LYMPHIR Scores Game-Changing Medicare Code! 🔥
Here's the scoop: The Centers for Medicare & Medicaid Services (CMS) just awarded LYMPHIR a permanent J-code (J9161), effective April 1, 2025. (2)(4)
Why does this
matter? Because it's like getting a VIP pass to the healthcare system – smoother billing, faster reimbursement, and a clear path to commercial success.
❤️ The Numbers That Make Investors' Hearts Race: (2)(4)
- Market Potential: A stunning $300-400M+ in the U.S. alone
- Projected Revenue: Scaling from $15M in 2025 to $78M+ by 2026
- EPS Growth: From -$5.97 to a projected $4.72 by 2026 (talk
about a glow-up!)
🎯 Why LYMPHIR is the Talk of the Town: (2)(4)
- First and only immunotherapy for relapsed/refractory CTCL
- 36% objective response rate, with some patients achieving complete remission
- Serves 3,000-4,000 new U.S. patients annually with no existing cure
- FDA approval already secured (August 2024)
But wait – Citius isn't just a one-hit
wonder. They're building an empire with a portfolio that reads like a greatest hits album:
🌟 Mino-Lok®: The $1.8B Market Game-Changer (2)(4)
- Revolutionary antibiotic solution for infected central venous catheters
- Phase 3 trials completed with stellar results
- Targeting 7 million annual U.S. catheter placements
- Could become the new gold standard in infection
prevention
🌟 Halo-Lido: The First of Its Kind (2)(4)
- Only prescription hemorrhoid treatment in development
- Phase 2b trials showed impressive symptom reduction
- Target market: 10 million patients, with one-third seeking physician care
- Positioned to dominate a market currently limited to over-the-counter options
🌟 The Hidden Gem: Citius Oncology (NASDAQ: CTOR) (2)(4)
- Citius owns 92% of this focused cancer therapy subsidiary
- Spearheading LYMPHIR's commercialization
- Exploring combinations with blockbuster drugs like KEYTRUDA®
- Potential to unlock multi-billion dollar oncology markets
⏰ Why Time Is of the Essence:
- LYMPHIR commercial launch: First half of 2025
- Founders have invested $26.5M of their own money (that's confidence you can't
fake)
- NASDAQ listing stabilized and primed for growth
- Multiple revenue streams coming online
With a 48.07% projected annual earnings growth rate and strong analyst backing, the current price feels like finding Amazon in 1997. (4)
The numbers aren't just impressive – they're screaming "look at me."
🎬 The Decision Point: While others are still debating
whether to join the party, industry insiders are already counting their RSVPs.
The biotech sector moves fast, and opportunities like this don't send save-the-dates. Remember our last feature that popped double digits? Citius Pharmaceuticals (NASDAQ: CTXR) is setting up to be even more exciting.
Remember: The market rewards the bold, but it especially rewards the early.
Those who see the signals before they become headlines are the ones with
the best stories to tell.
Stay ahead. Stay informed. But most importantly – stay in the game.
To your success,
Max Masters
Co-founder, Market Tips Newsletter
Sources:
1. https://finance.yahoo.com/quote/CTXR/
2. https://bit.ly/432P3oz
3.
https://bit.ly/4k5fb8b
4. https://bit.ly/4gtKUhJ
5. https://bit.ly/3XRl7sH
6. https://bit.ly/4hKa1gp
7. https://bit.ly/432Pcs7
8. https://bit.ly/3XN4q1o
